Correlation Between Edgewise Therapeutics and UroGen Pharma

Can any of the company-specific risk be diversified away by investing in both Edgewise Therapeutics and UroGen Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Edgewise Therapeutics and UroGen Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Edgewise Therapeutics and UroGen Pharma, you can compare the effects of market volatilities on Edgewise Therapeutics and UroGen Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Edgewise Therapeutics with a short position of UroGen Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Edgewise Therapeutics and UroGen Pharma.

Diversification Opportunities for Edgewise Therapeutics and UroGen Pharma

-0.7

Correlation Coefficient

Edgewise Therapeutics  UroGen Pharma

Excellent diversification

The 3 months correlation between Edgewise and UroGen is -0.7. Overlapping area represents the amount of risk that can be diversified away by holding Edgewise Therapeutics and UroGen Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on UroGen Pharma and Edgewise Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Edgewise Therapeutics are associated (or correlated) with UroGen Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of UroGen Pharma has no effect on the direction of Edgewise Therapeutics i.e., Edgewise Therapeutics and UroGen Pharma go up and down completely randomly.

Pair Corralation between Edgewise Therapeutics and UroGen Pharma

Given the investment horizon of 90 days Edgewise Therapeutics is expected to under-perform the UroGen Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Edgewise Therapeutics is 1.08 times less risky than UroGen Pharma. The stock trades about -0.05 of its potential returns per unit of risk. The UroGen Pharma is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  1,220  in UroGen Pharma on September 2, 2024 and sell it today you would earn a total of  50.00  from holding UroGen Pharma or generate 4.1% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Edgewise Therapeutics  vs.  UroGen Pharma

Edgewise Therapeutics

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Edgewise Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Edgewise Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

UroGen Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days UroGen Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, UroGen Pharma is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with Edgewise Therapeutics and UroGen Pharma

The main advantage of trading using opposite Edgewise Therapeutics and UroGen Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Edgewise Therapeutics position performs unexpectedly, UroGen Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will offset losses from the drop in UroGen Pharma's long position.

The idea behind Edgewise Therapeutics and UroGen Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.